Spencer Pharmaceutical Inc. (SPPH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 3.69: the stock has moved about 269% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSpencer Pharmaceutical Inc. (SPPH) trades at $0.0001. Spencer Pharmaceutical Inc. specializes in developing drug platform technologies for neurological diseases, focusing on controlled release of therapeutic molecules. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for SPPH: SPPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Spencer Pharmaceutical Inc. (SPPH) Healthcare & Pipeline Overview
Spencer Pharmaceutical Inc. is a pharmaceutical company focused on developing drug platform technologies for neurological diseases, including Alzheimer's and Parkinson's. The company's patented slow-release drug delivery technology aims to improve treatment efficacy and patient outcomes in North America and Europe, operating in a competitive pharmaceutical landscape.
What Is the Investment Thesis for SPPH?
Spencer Pharmaceutical Inc. presents a high-risk, high-reward investment opportunity within the pharmaceutical sector. The company's focus on neurological diseases and patented drug delivery technology offers potential for significant growth if clinical trials are successful and regulatory approvals are obtained. However, the company's OTC listing and lack of profitability indicate substantial risks. Key value drivers include successful clinical trial outcomes for its lead drug candidates targeting Alzheimer's and Parkinson's diseases. Upcoming milestones include the advancement of its slow-release drug delivery technology for type-2 diabetes into clinical trials. Investors should closely monitor the company's ability to secure funding, navigate regulatory hurdles, and establish strategic partnerships. The high beta of 3.69 suggests significant volatility, reflecting the speculative nature of the investment.
Based on FMP financials and quantitative analysis
SPPH Key Highlights
Focus on neurological diseases such as Alzheimer's and Parkinson's, addressing a significant unmet medical need.
- Patented slow-release drug delivery technology offers potential for improved drug efficacy and reduced side effects.
- Operations in North America and Europe provide access to key pharmaceutical markets.
- OTC listing indicates higher risk and lower liquidity compared to major exchange-listed companies.
- No dividend yield reflects the company's focus on reinvesting earnings into research and development.
Who Are SPPH's Competitors?
SPPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPPH's Key Strengths?
Patented slow-release drug delivery technology.
- Focus on neurological diseases with high unmet needs.
- Operations in North America and Europe.
- Expertise in controlled release formulations.
What Are SPPH's Weaknesses?
OTC listing indicates higher risk and lower liquidity.
- Limited financial resources.
- Dependence on clinical trial success.
- Lack of profitability.
What Are the Key Risks for SPPH?
Financial-distress signal — its Altman Z-Score of -2.29 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-50.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures could significantly impact the company's value.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from larger pharmaceutical companies with greater resources.
- OTC listing indicates higher risk and lower liquidity.
- Shell risk detected suggests potential for questionable business practices.
What Are SPPH's Competitive Advantages?
- Patented slow-release drug delivery technology provides a competitive advantage.
- Focus on neurological diseases with high unmet medical needs.
- Expertise in controlled release formulations.
- Established operations in North America and Europe.
What Does SPPH Do?
Spencer Pharmaceutical Inc., incorporated in 1998 and based in Boston, Massachusetts, is a pharmaceutical company dedicated to the development of innovative drug platform technologies. The company focuses on creating solutions for neurological diseases, including Alzheimer's and Parkinson's disease, as well as brain cancer. Spencer Pharmaceutical specializes in the controlled release of existing therapeutic molecules, aiming to improve drug efficacy and reduce side effects. Their patented slow-release drug delivery technology also targets other conditions such as type-2 diabetes and arthritis, showcasing the versatility of their platform. Spencer Pharmaceutical operates primarily in North America and Europe, seeking partnerships and collaborations to expand its market reach and accelerate the development of its drug candidates. The company's strategy involves identifying existing therapeutic molecules with proven efficacy but limited delivery mechanisms, then applying its proprietary technology to create enhanced formulations. This approach allows Spencer Pharmaceutical to potentially reduce development timelines and costs compared to developing entirely new chemical entities. The company's commitment to addressing unmet medical needs in neurological diseases and chronic conditions positions it within a competitive yet promising segment of the pharmaceutical industry. Spencer Pharmaceutical's success hinges on its ability to navigate the regulatory landscape, secure funding for clinical trials, and establish strategic partnerships to commercialize its innovative drug delivery technologies.
What Products and Services Does SPPH Offer?
- Develop drug platform technologies for neurological diseases.
- Specialize in controlled release of existing therapeutic molecules.
- Target central nervous system disorders like Alzheimer's and Parkinson's.
- Develop patented slow-release drug delivery technology.
- Focus on treatments for type-2 diabetes and arthritis.
- Conduct operations primarily in North America and Europe.
How Does SPPH Make Money?
- Develop proprietary drug delivery technologies.
- License or partner with pharmaceutical companies for commercialization.
- Generate revenue through royalties and milestone payments.
- Focus on improving existing drugs through novel delivery methods.
What Industry Does SPPH Operate In?
Spencer Pharmaceutical Inc. operates within the competitive pharmaceutical industry, specifically targeting the neurological disease market. This market is characterized by significant unmet medical needs and a growing aging population, driving demand for innovative therapies. The company's focus on controlled-release drug delivery technology aligns with the industry trend towards improving drug efficacy and patient adherence. Competitors include companies like BIOIF (Biofrontera Inc.) and CBGL (CBGL Long Blockchain Corp.), which are also developing novel therapies and drug delivery systems. The pharmaceutical industry is subject to stringent regulatory requirements and faces challenges related to clinical trial success, patent protection, and market access.
Who Are SPPH's Key Customers?
- Pharmaceutical companies seeking innovative drug delivery technologies.
- Patients suffering from neurological diseases and chronic conditions.
- Healthcare providers prescribing medications for targeted conditions.
- Research institutions collaborating on drug development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Spencer Pharmaceutical Inc. stands at -50.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.4%, showing how much profit it generates from its asset base. A current ratio of 0.79 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Spencer Pharmaceutical Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Maximilien Arella. SPPH has traded publicly since 2023.
Financial Health
Spencer Pharmaceutical Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.29 places it in the distress zone, a signal of elevated financial risk.
SPPH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SPPH Latest News
No recent news available for SPPH.
SPPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SPPH.
Price Targets
Wall Street price target analysis for SPPH.
SPPH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SPPH; grades run from A+ (80-100) to F (below 30).
Leadership: Maximilien Arella
CEO
Maximilien Arella is the Chief Executive Officer of Spencer Pharmaceutical Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization. Prior to joining Spencer Pharmaceutical, Mr. Arella held leadership positions at several biotechnology companies, where he oversaw the development and launch of novel therapies. He holds an MBA from a top-tier business school and a Ph.D. in pharmaceutical sciences.
Track Record: Since assuming the role of CEO, Maximilien Arella has focused on advancing Spencer Pharmaceutical's drug pipeline and securing strategic partnerships. He has overseen the development of the company's patented slow-release drug delivery technology and has been instrumental in securing funding for clinical trials. Under his leadership, Spencer Pharmaceutical has expanded its operations in North America and Europe.
SPPH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Spencer Pharmaceutical Inc. may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Compared to companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies have less stringent listing requirements and may not be subject to the same level of scrutiny.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in SPPH.
- Low trading volume can lead to price volatility and illiquidity.
- OTC Other tier status indicates a higher risk of fraud or manipulation.
- Shell risk detected suggests potential for questionable business practices.
- Dependence on successful clinical trials and regulatory approvals.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's intellectual property and patent portfolio.
- Evaluate the potential market for the company's products and services.
- Determine the company's cash flow and funding requirements.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC stocks.
- Focus on developing drug platform technologies for neurological diseases.
- Patented slow-release drug delivery technology.
- Operations in North America and Europe.
- Experienced CEO with a background in the pharmaceutical industry.
What Investors Ask About Spencer Pharmaceutical Inc. (SPPH) — Healthcare
What do analysts say about SPPH stock?
As of March 17, 2026, there is no available analyst coverage or consensus rating for Spencer Pharmaceutical Inc. (SPPH) due to its listing on the OTC market and limited financial disclosure. Key valuation metrics such as price-to-earnings ratio are not meaningful due to the company's lack of profitability.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and disclosure status.